Calidi Biotherapeutics (CLDI) vs Curis (CRIS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Calidi Biotherapeutics is the larger company by market cap ($3.8 million vs $1.7 million), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDI | CRIS |
|---|---|---|
| Share price | $1.04 | $0.7094 |
| Market cap | $3.82M | $1.72M |
| 1-day change | +2.97% | -3.69% |
| P/E ratio (TTM) | — | 0.54 |
| EPS (TTM) | $-36.47 | $1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.84 | $33.60 |
| 52-week low | $0.986 | $0.61 |
| Distance from 52-week high | -96.26% | -97.89% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +5914.94% |
| Average volume | 255.53K | 199.15K |
| Shares outstanding | 3.68M | 2.43M |
| Employees | 29 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Calidi Biotherapeutics is about 2.2 times larger than Curis by market value ($3.82M vs $1.72M).
About Calidi Biotherapeutics
CLDI stock →Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 29 employees
About Curis
CRIS stock →Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
CLDI vs CRIS FAQ
Which is bigger, Calidi Biotherapeutics or Curis?
Calidi Biotherapeutics (CLDI) is larger, with a market capitalization of $3.82M compared with $1.72M for Curis (CRIS).
Are Calidi Biotherapeutics and Curis in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.